Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
Current international guidelines recommend either boosted protease inhibitor (PI/r)-based or integrase inhibitors (INSTI)-based regimens during primary HIV infection (PHI), even though the latter have only demonstrated their superiority at the chronic stage. We compared the effectiveness of INSTI- versus PI/r-based combined antiretroviral therapy (cART) initiated during PHI. This study was conducted among patients who initiated cART between 2013 and 2017, using data from the ANRS-PRIMO cohort and the Dat'AIDS study. Cumulative proportions of patients reaching viral suppression (HIV-1 RNA <50 cp/mL) were calculated using Turnbull's estimator for interval-censored data. CD4 cells and CD4/CD8 ratio increases were estimated using mixed linear models. Results were adjusted for the data source. Among the 712 study patients, 299 received an INSTI-based cART. Patients baseline characteristics were similar between groups. Viral suppression was reached more rapidly in INSTI- versus PI/r-treated patients (p < 0.01), with cumulative proportions of 37% vs 6% at 4 weeks, 77% vs 38% at 12 weeks, 92% vs 79% at 24 weeks and 93% in both groups at 48 weeks. At 4 weeks, INSTI-treated patients had gained on average 40 CD4 cells/μl (p=0.05) over PI/r-treated ones; mean CD4 counts were similar in the two groups at 48 weeks. The CD4/CD8 ratio followed the same pattern. Results were similar when restricted to a comparison between Dolutegravir- vs Darunavir-based cART. Based on this study and available literature, we recommend the use of INSTI-based cART for treatment initiation during PHI, since it leads to faster viral suppression and immune restoration.